Glucagon-like peptide 1 receptor… (NCT07107334)

Name: Glucagon-like peptide 1 receptor agonist trial for Endometrioid Endometrial Adenocarcinoma (NCT07107334)
Uploaded: 2026-10-31T21:16:33.335Z
Duration: 1 min 14 s
Description: Glucagon-like peptide 1 receptor agonist trial for Endometrioid Endometrial Adenocarcinoma (NCT07107334). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07107334.

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia: a one-minute explainerNCT071073341 min

Glucagon-like peptide 1 receptor agonist trial for Endometrioid Endometrial Adenocarcinoma (NCT07107334). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult women with obesity and endometrial precancer or grade-one endometrioid cancer without muscle invasion or spread. They must want fertility preservation or have substantial surgical risk.

The idea: combine a levonorgestrel-releasing intrauterine device with a GLP-1 drug to support weight loss. The device releases hormone locally; levonorgestrel may limit endometrial cell growth. Researchers assess disease response and readiness for hysterectomy or pregnancy.

This phase 2 study plans 20 patients. Kaitlin Nicholson leads at the University of Florida in Gainesville, the sole recruiting US site. Drug choice is individualized.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.